<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04055922</url>
  </required_header>
  <id_info>
    <org_study_id>058.PHA.2017.D</org_study_id>
    <nct_id>NCT04055922</nct_id>
  </id_info>
  <brief_title>Comparison of Solid Organ Transplant</brief_title>
  <official_title>Comparison of Solid Organ Transplant Specific and Hospital-wide Gram-Negative Antibiograms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Methodist Health System</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Methodist Health System</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Solid organ transplant (SOT) recipients have increased incidence of infections with MDRO&#xD;
      pathogens. This difference leads to a disparity in antibiograms between SOT recipients and&#xD;
      other hospitalized patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is limited guidance for empiric antimicrobial therapy in this population. Local&#xD;
      epidemiology plays a voluble role in managing infections empirically within the hospital&#xD;
      setting. Antibiograms can serve as a critical tool in optimizing empiric antimicrobial&#xD;
      decisions. Refining antibiogram data to specific populations such as SOT patients may allow&#xD;
      for timelier and appropriate empiric use of antimicrobials, and improve clinical outcomes.&#xD;
&#xD;
      Time to appropriate therapy (antimicrobial testing susceptible in vitro to the pathogen&#xD;
      identified) is of vital importance in management of serious infections. SOT may have&#xD;
      different resistance rates at Methodist Dallas Medical Center making the applicability of the&#xD;
      yearly hospital-wide antibiogram unknown for use in this specialized patient population. A&#xD;
      SOT-Specific antibiogram may highlight common resistance patterns identified in pathogens&#xD;
      seen in this patient population. Additionally, this investigation may further emphasize the&#xD;
      importance of antimicrobial stewardship activities such as: appropriate empiric antibacterial&#xD;
      decisions, de-escalation, and effective durations of therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Enrolling by invitation</last_known_status>
  <start_date type="Actual">May 3, 2018</start_date>
  <completion_date type="Anticipated">May 2021</completion_date>
  <primary_completion_date type="Anticipated">May 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Creation of a liver transplant specific antibiogram</measure>
    <time_frame>Jan 1, 2012 - December 31, 2016</time_frame>
    <description>Creation of a liver transplant specific antibiogram (cumulative susceptibility rates per bacterial organism for select antibiotics)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Creation of a kidney transplant specific antibiogram</measure>
    <time_frame>Jan 1, 2012 - December 31, 2016</time_frame>
    <description>Creation of a kidney transplant specific antibiogram (cumulative susceptibility rates per bacterial organism for select antibiotics)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Comparison of SOT</measure>
    <time_frame>Jan 1, 2012 - December 31, 2016</time_frame>
    <description>Comparison of SOT (liver and kidney) antibiograms with the hospital-wide antibiogram</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Creation of transplant antibiogram for subgroups</measure>
    <time_frame>Jan 1, 2012 - December 31, 2016</time_frame>
    <description>Creation of transplant antibiogram for subgroups of patients including the following: ICU patients, Kidney transplant urinary tract infections (UTI), SOT bloodstream infections (BSI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Identification of risk factors among liver transplant recipients</measure>
    <time_frame>Jan 1, 2012 - December 31, 2016</time_frame>
    <description>Identification of risk factors among liver transplant recipients for vancomycin-resistant enterococci infections</description>
  </secondary_outcome>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Gram-Negative Bacterial Infections</condition>
  <condition>Gram-negative Bacteremia</condition>
  <condition>Multidrug-Resistant Organism</condition>
  <condition>Hospital-acquired Pneumonia</condition>
  <condition>Healthcare-associated Pneumonia</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Solid organ transplant (SOT) recipients&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 years or older&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Missing data necessary to determine study outcomes&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matt Crotty, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Methodist Health System</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Methodist Dallas Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>August 12, 2019</study_first_submitted>
  <study_first_submitted_qc>August 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 14, 2019</study_first_posted>
  <last_update_submitted>December 30, 2019</last_update_submitted>
  <last_update_submitted_qc>December 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Bacterial Infections</mesh_term>
    <mesh_term>Bacteremia</mesh_term>
    <mesh_term>Healthcare-Associated Pneumonia</mesh_term>
    <mesh_term>Gram-Negative Bacterial Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

